Connect with us

Psilocybin

News You Might Have Missed: Feb 14th, 2022

The article News You Might Have Missed: Feb 14th, 2022 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup…

Published

on

This article was originally published by https://microdose.buzz/news/203893/

The article News You Might Have Missed: Feb 14th, 2022 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed. 

It was a busy week with lots of news, have a look and see you next week for another update.

 

Cybin Granted DMT Patent for CYB004

CYB004 is Cybin’s lead investigational proprietary DMT compound. In preclinical studies, CYB004 has demonstrated potential efficacy at lower doses while also increasing the duration of drug effect providing a therapeutic profile that may alleviate the common negative experiences associated with classical DMT.

 

Star Investor Cathie Wood Finally Buys Into Psychedelics

ARK Genomic Revolution ETF bought 83,278 shares of Atai Life Sciences, its first foray into psychedelics. The results were immediate, with positive price movement across the sector.

 

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica facility and grows roster of supply partners in the U.S. market.

 

Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents

Awakened’s novel production methods have resulted in the filing of three (3) provisional patents applications with the United States Patent and Trademark Office (USPTO) for protection of these proprietary technologies.

 

Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada

Mydecine now able to supply cGMP products to healthcare providers for patients with serious and life-threatening conditions through the Special Access Program

 

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

“During the quarter, we continued to make tremendous progress advancing our proprietary psychedelic-based molecules toward clinical development – reaching regulatory milestones, completing numerous preclinical studies, and establishing reliable supply chains in the U.S. and the UK,” said Doug Drysdale, Chief Executive Officer of Cybin.

 

Optimi Health Dealer’s License Granted by Health Canada

The Dealer’s License allows for possession, production, assembling, sale, and delivery of psilocybin within the regulated framework set forth by Health Canada. Optimi will now launch vertically integrated operations at its facility in Princeton, B.C

 

Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed

 

Read More

Trending